Nuveen LLC Acquires New Position in ICU Medical, Inc. $ICUI

Key Points

• Nuveen LLC acquired 77,973 shares of ICU Medical, Inc., valued at approximately $10.83 million, during the first quarter, giving them a stake of 0.32% in the company.
• ICU Medical's latest earnings report revealed an EPS of $2.10 for the quarter, exceeding analysts' predictions, but its quarterly revenue was down 8.0% compared to the previous year.
• CEO Vivek Jain increased his position in the company by acquiring 21,929 shares at an average price of $112.84, while COO Christian B. Voigtlander sold 4,985 shares at an average price of $128.50.

Nuveen LLC purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 77,973 shares of the medical instruments supplier's stock, valued at approximately $10,827,000. Nuveen LLC owned approximately 0.32% of ICU Medical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in ICUI. Quarry LP boosted its holdings in ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 214 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in ICU Medical by 88.8% during the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 300 shares in the last quarter. GAMMA Investing LLC boosted its holdings in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 153 shares in the last quarter. Blue Trust Inc. boosted its holdings in ICU Medical by 23.0% during the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after buying an additional 150 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in ICU Medical by 87.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,352 shares of the medical instruments supplier's stock worth $210,000 after buying an additional 632 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ICUI shares. Piper Sandler started coverage on shares of ICU Medical in a report on Friday, August 15th. They set an "overweight" rating and a $145.00 price target on the stock. Wall Street Zen cut shares of ICU Medical from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Raymond James Financial reduced their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $179.00.

ICU Medical Price Performance

NASDAQ:ICUI traded up $0.42 during trading hours on Thursday, reaching $127.04. 219,661 shares of the company were exchanged, compared to its average volume of 404,625. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average is $126.87 and its 200-day moving average is $136.15. The firm has a market cap of $3.14 billion, a PE ratio of -83.58 and a beta of 0.88. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Transactions at ICU Medical

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of ICU Medical stock in a transaction dated Wednesday, August 27th. The stock was acquired at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares of the company's stock, valued at approximately $1,006,303.20. This represents a 17.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain bought 21,929 shares of ICU Medical stock in a transaction dated Thursday, August 14th. The stock was acquired at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the transaction, the chief executive officer directly owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by corporate insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.